All PlansCoverageMedium impact
Voluntary nationwide recall: Atorvastatin (Alkem – October)
UPMC Health Plan·Cardiology, Endocrinology, Internal Medicine +2 more·Pharmacy
Effective date
Oct 10, 2025
We identified it
Aug 7, 2026
Summary
Ascend Laboratories LLC is voluntarily recalling multiple lots of Atorvastatin Calcium Tablets USP due to improper dissolution rates that may reduce drug effectiveness. Patients with affected lots should stop use immediately and return medication to pharmacy or discard. Billing teams must communicate this recall to providers and be prepared to address potential claim adjustments or medication therapy management related to affected prescriptions.
Action Required
Immediately: Clinical staff and billing team must coordinate with prescribing providers to identify patients receiving recalled Atorvastatin lots. Flag affected patient accounts in billing system. Contact pharmacy to verify which lots are affected using FDA resources. Notify affected patients through standard recall channels. Billing team should monitor for potential rebilling of alternative statin therapy and document recall-related medication switches in patient records. No claims should be denied for patients who discontinue recalled medication per FDA guidance. Confirm with payers (UPMCHealthPlan noted in source URL) regarding any claim adjustments or prior authorization requirements for alternative medications prescribed as replacements.